Evidence map›Paper›PMID 34529143›Full record

ReviewArchivum immunologiae et therapiae experimentalis2021

Are Host Defense Peptides and Their Derivatives Ready to be Part of the Treatment of the Next Coronavirus Pandemic?

Bruno Rivas-Santiago, Yolanda Jacobo-Delgado, Adrian Rodriguez-Carlos

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Archivum immunologiae et therapiae experimentalis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Frontiers in immunology · 2023
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bruno Rivas-SantiagoBiomedical Research Unit-Zacatecas, Mexican Institute for Social Security-IMSS, Col. Centro Zacatecas, Interior of Alameda #45, Zacatecas, Mexico. rondo_vm@yahoo.com.ORCID http://orcid.org/0000-0002-1521-1519
Yolanda Jacobo-DelgadoBiomedical Research Unit-Zacatecas, Mexican Institute for Social Security-IMSS, Col. Centro Zacatecas, Interior of Alameda #45, Zacatecas, Mexico.ORCID http://orcid.org/0000-0003-2174-6277
Adrian Rodriguez-CarlosBiomedical Research Unit-Zacatecas, Mexican Institute for Social Security-IMSS, Col. Centro Zacatecas, Interior of Alameda #45, Zacatecas, Mexico.ORCID http://orcid.org/0000-0002-3514-5299

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The term host defense peptides arose at the beginning to refer to those peptides that are part of the host's immunity. Because of their broad antimicrobial capacity and immunomodulatory activity, nowadays, they emerge as a hope to combat resistant multi-drug microorganisms and emerging viruses, such as the case of coronaviruses. Since the beginning of this century, coronaviruses have been part of different outbreaks and a pandemic, and they will be surely part of the next pandemics, this review analyses whether these peptides and their derivatives are ready to be part of the treatment of the next coronavirus pandemic.

Indexed as

PandemicsAnti-Inflammatory AgentsAntimicrobial Cationic PeptidesAntiviral AgentsClinical Trials as TopicCoronavirusCoronavirus InfectionsHumansImmunomodulationRespiratory Tract InfectionsAnti-Inflammatory AgentsAntimicrobial Cationic PeptidesAntiviral AgentsAntimicrobial peptidesCathelicidinCoronavirusDefensinHost defense peptidesTreatment

Identifiers

PMID34529143
PMCPMC8444179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.